Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the
SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise
novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Media
Press Releases - latest
Newron to initiate Phase IIb/III study of Ralfinamide in patients with Neuropathic Low Back Pain (NLBP)22/12/2008
|
ENG
|
GER
|
|
Newron Consortium Grant22/12/2008
|
ENG
|
GER
|
|
Change in Newron Group Management19/12/2008
|
ENG
|
GER
|
|
Newron secures CHF30m long term standby equity line
03/12/2008
|
ENG
|
GER
|
|
Newron reports positive Phase II safety and tolerability results for HF0220 in Alzheimer’s disease
23/10/2008
|
ENG
|
GER
|